News

Hyqvia is a combination of Immune Globulin Infusion 10% (Human) (IG 10%) and Recombinant Human Hyaluronidase developed by Halozyme. The first subcutaneous immune globulin (IG) treatment is approved

CLT-008 is a first-in-class, allogeneic, cell-based therapy to treat hematopoietic sub-syndrome of Acute Radiation Syndrome (ARS). The recent funding is in addition to the $116.4m committed under the

The approval allows the tablets for use in chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27

The discovery of dendritic cells in 1973, resulting in a 2011 Nobel Prize in Physiology or Medicine, bridged the two principal aspects of immunity (innate and adaptive) first

The Company will use the information generated to advance one or more candidates into formal development studies in the coming months. Prosonix’ MCP Technology allows the combination of

These grants support a global intellectual property estate broadly covering the Company’s biochemistry and delivery technologies with over 100 issued or allowed patents and over 90 pending U.S.

The supplement features a discussion on available clinical evidence from trials conducted in patients with diabetic foot ulcers (DFUs). The authors, Dr. Lawrence Lavery, Professor of Surgery, University

Paul DiTullio, Vice President, Product Development remarked, "The major advantages of the Company’s nanoRNA technology over other antisense, gene-silencing and RNAi technologies is a proprietary chemistry that overcomes

The Phase IIb trial was assessing the safety and tolerability of Oxycyte in patients with severe non-penetrating traumatic brain injury (STOP-TBI). The decision to halt the trial comes